BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Sickle Cell Disease

In brief

This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD

Key facts

Study ID
NCT05456880
Run by
Beam Therapeutics Inc.
People needed
15
Starts
2022-08-30
Expected to finish
2028-02-01
Last updated by the study team
2025-12-16

Who can join

Age: 12 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.